Abeona Therapeutics Inc. Common Stock (ABEO)

About ABEO

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

226

Website

abeonatherapeutics.com/

Fundamentals

1-day range

$6.17$6.32

Market cap

$393.27M

P/E (trailing)

5.50

P/E (forward)

-33.68

EPS (trailing)

$0.87

Dividend yield

—

Beta

1.28

Avg. volume

1.37M

Forecasts

7 analyst ratings

Abeona Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ABEO

  Abeona Therapeutics Inc. Common Stock

  $5.92

  ▼ 1.99%
  Market cap $393.27MP/E 5.50
  $4$7.65
• ENTA

  Enanta Pharmaceuticals Inc. Common Stock

  $13.6

  ▼ 1.45%
  Market cap $387.91MP/E —
  $7.05$17.15
• RCKT

  Rocket Pharmaceuticals Inc. Common Stock

  $3.86

  ▲ 6.49%
  Market cap $386.55MP/E —
  $2.53$5.45
• UPB

  Upstream Bio Inc. Common Stock

  $6.68

  ▼ 1.62%
  Market cap $373.87MP/E —
  $5.85$33.68
• PBYI

  Puma Biotechnology Inc Common Stock

  $9.07

  ▼ 1.89%
  Market cap $413.30MP/E 18.65
  $4.3$9.51
• ASMB

  Assembly Biosciences Inc. Common Stock

  $33.97

  ▼ 2.39%
  Market cap $420.36MP/E 333.50
  $20.23$39.71
• DMAC

  DiaMedica Therapeutics Inc. Common Stock

  $6.39

  ▼ 5.33%
  Market cap $364.79MP/E —
  $5.14$10.42

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Abeona Therapeutics Inc (ABEO) (Q2 2026) Earnings Call Highlights: ZEVASKYN Revenue Surges 31% ...
  Yahoo · 8/17/2026
• ABEO: Zevaskyn® Launch Gains Momentum
  Yahoo · 8/17/2026
• Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21
  Benzinga · 8/14/2026
• Abeona Therapeutics Inc. Q2 2026 Earnings Call Summary
  Yahoo · 8/13/2026
• Abeona Therapeutics: Earnings Sell-Off Could Be A Buy Opportunity
  SeekingAlpha · 8/13/2026
• Abeona Therapeutics Q2 Earnings Call Highlights
  Yahoo · 8/13/2026
• Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/13/2026
• Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
  Yahoo · 8/13/2026

• Joseph Walter Vazzano · July 21, 2026 · Sale

  1.5K @ $6.53
• Madhav Vasanthavada · July 9, 2026 · Sale

  12.6K @ $6.96
• Brendan M. O'Malley · July 9, 2026 · Sale

  12.1K @ $6.96
• Vishwas Seshadri · July 9, 2026 · Sale

  68.0K @ $6.96
• Joseph Walter Vazzano · July 9, 2026 · Sale

  24.9K @ $6.96
• Leila Alland · June 30, 2026 · Sale

  11.0K @ $5.92
• Christine Berni Silverstein · June 15, 2026 · Sale

  18.2K @ $5.71
• Madhav Vasanthavada · June 9, 2026 · Sale

  5.5K @ $5.3
• Brendan M. O'Malley · June 9, 2026 · Sale

  6.3K @ $5.3
• Vishwas Seshadri · June 9, 2026 · Sale

  31.9K @ $5.3
• Joseph Walter Vazzano · June 9, 2026 · Sale

  25.6K @ $5.39
• Joseph Walter Vazzano · June 9, 2026 · Sale

  13.4K @ $5.3
• Madhav Vasanthavada · June 8, 2026 · Sale

  4.2K @ $5.43
• Brendan M. O'Malley · June 8, 2026 · Sale

  4.8K @ $5.43
• Vishwas Seshadri · June 8, 2026 · Sale

  24.4K @ $5.43

Institutional Ownership

March 31, 2026

Total shares held

40.68M

Total value held

$182.02M

Institutional holders

102